Related Experiment Video
Updated: Jun 22, 2026
05:52
Prehospital Thrombolysis: A Manual from Berlin
Published on: November 26, 2013
Reprogrammed streptokinases develop fibrin-targeting and dissolve blood clots with more potency than tissue
I Y Sazonova1, R A McNamee, A K Houng
1Cardiovascular Research Medical College of Georgia, Augusta, GA, USA.
Journal of Thrombosis and Haemostasis : JTH
|July 2, 2009
Summary
Reprogramming streptokinase (SK) created new plasminogen activators (PAs) with enhanced fibrin-targeting and potency. These novel PAs, SKDelta1 and SKDelta59, show greater effectiveness in dissolving blood clots compared to tissue plasminogen activator (TPA).
Area of Science:
- Biochemistry
- Molecular Biology
- Cardiovascular Research
Background:
- Cardiovascular diseases are a global epidemic, necessitating improved thrombolytic therapies.
- Current plasminogen activators (PAs) like streptokinase (SK) and tissue plasminogen activator (TPA) dissolve blood clots but have limitations.
- SK is less effective due to a lack of fibrin-targeting, unlike TPA.
Purpose of the Study:
- To investigate if modifying SK's mechanism could yield PAs with superior fibrin-targeting and potency compared to TPA.
- To develop novel thrombolytic agents for more effective treatment of thrombotic events.
Main Methods:
- Reprogramming streptokinase (SK) to create novel molecules SKDelta1 and SKDelta59.
- Assessing fibrin-dependency by measuring fibrinogen consumption in human plasma.
- Evaluating in vivo efficacy using a humanized fibrinolysis mouse model.
- Comparing the potency of reprogrammed SK variants against TPA.
Main Results:
- SKDelta1 and SKDelta59 demonstrated significantly higher fibrin-dependency than both SK and TPA in human plasma.
- SKDelta59 exhibited marked fibrin-targeting, processing only fibrin-bound plasminogen and resisting inhibition.
- In vivo studies showed SKDelta1 and SKDelta59 were 4-fold and 2-fold more potent than TPA, respectively, in dissolving blood clots.
Conclusions:
- Reprogramming SK's mechanism substantially enhances fibrin-targeting.
- The modified SK variants (SKDelta1, SKDelta59) exhibit greater fibrinolytic potency than TPA.
- These findings suggest potential for improved thrombolytic therapies in cardiovascular disease treatment.
Related Concept Videos
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:22Formation of the Platelet Plug
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...